By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Drugs and Therapies are presented in a new report. According to news reporting originating in Villejuif, France, by NewsRx journalists, research stated, "To evaluate an alternative dose point, so-called ALG (for Alain Gerbaulet), for the bladder in comparison to the International Commission on Radiation Units and Measurements (ICRU) point and D2cm(3) (minimal dose to maximally exposed 2 cm(3)) in a large cohort of patients with locally advanced cervical cancer treated with external beam radiotherapy followed by image-guided pulsed dose rate brachytherapy. For each patient, the ALG point was constructed 1.5 cm above the ICRU bladder, parallel to the tandem (coronal and sagittal planes)."
The news reporters obtained a quote from the research from the Department of Medical Physics, "The dosimetric data from 162 patients were reviewed. Average doses to ALG and bladder points were 19.40 Gy +/- 7.93 and 17.14 +/- 8.70, respectively (p = 0.01). The 2 cm(3) bladder dose averaged 24.40 +/- 6.77 Gy. Ratios between D2cm(3) and dose points were 1.37 +/- 0.46 and 1.68 +/- 0.74 (p < 0.001) for ALG and ICRU points, respectively. Both dose points appeared correlated with D2cm(3) (p < 0.001) with coefficients of determination (R-2) of 0.331 and 0.399 respectively. The estimated dose to the ICRU point of the rectum was 12.77 +/- 4.21 and 15.76 +/- 5.94 for D2cm(3) (p < 0.0001). Both values were significantly correlated (p < 0.0001, R-2 = 0.485). The ALG point underestimates the D2cm(3), but its mean on a large cohort is closer to D2cm(3) than the dose to ICRU point."
According to the news reporters, the research concluded: "However, it shows great variability between cases and the weak strength of its correlation to D2cm(3) indicates that it is not a good surrogate for individual volumetric evaluation of the dose D2cm(3)."
For more information on this research see: Volumetric evaluation of an alternative bladder point in brachytherapy for locally advanced cervical cancer. Strahlentherapie Und Onkologie, 2014;190(1):41-47. Strahlentherapie Und Onkologie can be contacted at: Urban & Vogel, Neumarkter Strasse 43, D-81673 Munich, Germany. (Springer - www.springer.com; Strahlentherapie Und Onkologie - www.springerlink.com/content/0179-7158/)
Our news correspondents report that additional information may be obtained by contacting R. Mazeron, Gustave Roussy, Dept. of Med Phys, F-94805 Villejuif, France. Additional authors for this research include J. Gilmore, J. Champoudry, I. Dumas, J. Helou, P. Maroun, F. Martinetti, A. Gerbaulet and C. Haie-Meder (see also Drugs and Therapies).
Keywords for this news article include: France, Europe, Cancer, Oncology, Villejuif, Radiotherapy, Brachytherapy, Drugs and Therapies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC